Clinical Trial Update: A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating SAGE-547 for severe postpartum depression has completed; results were posted in June 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postpartum Depression

Drugs mentioned

• SAGE-547 (brexanolone)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Postpartum Depression | Phase 3 | Status: COMPLETED | Results posted: 2019-06-13